Description
ndications |
Cerebrovascular and peripheral vascular disease. | ||||||||||||||||||
Dosage |
Adult : PO 10-20 mg 3-4 times/day. | ||||||||||||||||||
Dosage Details |
Oral Cerebrovascular and peripheral vascular diseaseAdult: 10-20 mg 3 or 4 times daily. |
||||||||||||||||||
Administration |
May be taken with or without food. May be taken w/ meals, milk or antacids to minimise GI discomfort. | ||||||||||||||||||
Contraindications |
Recent arterial haemorrhage. | ||||||||||||||||||
Special Precautions |
Pregnancy and lactation. Not intended to be given immediately postpartum. | ||||||||||||||||||
Adverse Drug Reactions |
Significant: Severe rash. Nervous: Trembling, nervousness, weakness, dizziness. CV: Palpitation, tachycardia, chest pain, hypotension, flushing. GI: Abdominal distress, nausea, vomiting, intestinal distention. |
||||||||||||||||||
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
||||||||||||||||||
Mechanism of Action |
Description: Isoxsuprine, a β-agonist, increases muscle blood flow by directly relaxing the vascular smooth muscle. Pharmacokinetics: Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: Approx 1 hr. Distribution: Crosses the placenta. Excretion: Excreted via urine as conjugates. Plasma elimination half-life: Approx 1.5 hr. |
||||||||||||||||||
Storage |
Store between 15-30°C. | ||||||||||||||||||
MIMS Class |
Peripheral Vasodilators & Cerebral Activators | ||||||||||||||||||
ATC Classification |
C04AA01 – isoxsuprine ; Belongs to the class of 2-amino-1-phenylethanol derivative agents. Used as peripheral vasodilators. | ||||||||||||||||||
